KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Gross Margin (2020 - 2023)

Historic Gross Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 66.23%.

  • AbCellera Biologics' Gross Margin fell 266400.0% to 66.23% in Q4 2023 from the same period last year, while for Dec 2023 it was 62.71%, marking a year-over-year decrease of 236100.0%. This contributed to the annual value of 55.68% for FY2024, which is 70300.0% down from last year.
  • As of Q4 2023, AbCellera Biologics' Gross Margin stood at 66.23%, which was down 266400.0% from 47.45% recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Gross Margin ranged from a high of 95.13% in Q2 2020 and a low of 47.45% during Q3 2023
  • In the last 4 years, AbCellera Biologics' Gross Margin had a median value of 86.42% in 2022 and averaged 81.45%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 85800bps in 2022, then crashed by -377200bps in 2023.
  • Quarter analysis of 4 years shows AbCellera Biologics' Gross Margin stood at 87.72% in 2020, then decreased by -4bps to 84.29% in 2021, then grew by 10bps to 92.87% in 2022, then dropped by -29bps to 66.23% in 2023.
  • Its Gross Margin was 66.23% in Q4 2023, compared to 47.45% in Q3 2023 and 61.8% in Q2 2023.